Further analysis of Phase III study of Pfizer Covid-19 vaccine confirms high efficacy and good safety profile up to 6 months following second dose

Analysis of 927 confirmed symptomatic cases of Covid-19 observed in the trial has shown that the vaccine was 91.3% effective against Covid-19, and 100% effective against severe disease, when measured 7 days through to 6 months after the second dose

Pfizer